Browse > Article

Efficacy and Safety of Albis$^{(R)}$ in Acute and Chronic Patients with Gastritis: A Double-blind, Placebo-controlled, Randomized Multi-center Study  

Han, Hae-Won (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
Choi, Myung-Gyu (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
Seol, Sang-Young (Department of Internal Medicine, *Pusan Paik Hospital, Inje University College of Medicine)
Lee, Dong-Ho (Department of Internal Medicine, Seoul National University College of Medicine)
Jung, Hwoon-Yong (Department of Internal Medicine, University of Ulsan College of Medicine)
Kim, Tae-Nyeun (Department of Internal Medicine, Yeungnam University College of Medicine)
Choi, Suck-Chei (Department of Internal Medicine, Wonkwang University College of Medicine)
Kim, Hyen-Soo (Department of Internal Medicine, Chonnam National University Medical School)
Publication Information
Clinical Endoscopy / v.42, no.4, 2011 , pp. 215-221 More about this Journal
Abstract
Background/Aims: Albis$^{(R)}$ is a newly developed drug comprised of ranitidine, bismuth and sucralfate. The aim of the study was to demonstrate the efficacy and safety superiority of Albis$^{(R)}$ compared to Stillen$^{(R)}$ for treating erosive gastritis. Methods: This study was a randomized, double-blind, multi-center trial. The primary endpoint was 2 weeks of treatment. Results: Of the 229 patients in the intention-to-treat (ITT) population, 87 from the Albis$^{(R)}$, and 96 from the Stillen$^{(R)}$ group were included in the per protocol (PP) analysis. The endoscopic improvement rate was not different between the Albis$^{(R)}$ group and the control in both the PP (42.5%, 39.6%) and ITT (35.3%, 34.5%) populations. The endoscopic cure of erosion was also not different in the Albis$^{(R)}$ group than that in the control group in both the PP (32.3%, 31.3%) and ITT (27.6%, 27.4%) populations. The endoscopic improvement rate for hemorrhage, edema, and erythema were also not different between the two groups in both the PP and ITT populations. No statistically significant differences were observed for adverse events between the two groups. Conclusions: Half of the approved dose of Albis$^{(R)}$ for peptic ulcers was superior to Stillen$^{(R)}$. A low dosage of Albis$^{(R)}$ is more cost efficient and safe than that of Stillen$^{(R)}$.
Keywords
Albis$^{(R)}$; Stillen$^{(R)}$; Erosive gastritis; Clinical trial;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ryu BK, Cho TS, Kim YM, Yeom JH, Yu YH. Therapeutic effects on gastrointestinal diseases of a new combined ranitidine preparations, DWP302. Biomolecules & Therapeutics 1994;2:185-189.
2 Seol SY, Kim MH, Ryu JS, Choi MG, Shin DW, Ahn BO. DA-9601 for erosive gastritis: results of a double-blind placebo- controlled phase III clinical trial. World J Gastroenterol 2004;10:2379-2382.   DOI
3 Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
4 Pazzi P, Gamberini S, Scagliarini R, Dalla Libera M, Merighi A, Gullini S. Misoprostol for the treatment of chronic erosive gastritis: a double-blind placebo-controlled trial. Am J Gastroenterol 1994;89:1007-1013.
5 Guslandi M. Comparison of sucralfate and ranitidine in the treatment of chronic nonerosive gastritis. A randomized, multicenter trial. Am J Med 1989;86:45-48.
6 Guslandi M, Ferrero S, Fusillo M. Sucralfate gel for symptomatic chronic gastritis: multicentre comparative trial versus sucralfate suspension. Ital J Gastroenterol 1994;26:442-445.
7 Kazi JI, Jafarey NA, Alam SM, et al. A placebo controlled trial of bismuth salicylate in Helicobacter pylori associated gastritis. J Pak Med Assoc 1990;40:154-156.
8 Yamagata S, Miura K. Therapeutic effects of cetraxate against acute gastritis and acute aggravation of chronic gastritis. Endoscopic investigation by the double-blind method. Arzneimittelforschung 1983;33:1191-1195.
9 Du Y, Li Z, Zhan X, et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci 2008;53:2886-2895.   DOI   ScienceOn
10 Sakamoto C, Ogoshi K, Saigenji K, et al. Comparison of the effectiveness of geranylgeranylacetone with cimetidine in gastritis patients with dyspeptic symptoms and gastric lesions: a randomized, double-blind trial in Japan. Digestion 2007;75:215-224.   DOI   ScienceOn
11 Skoubo-Kristensen E, Funch-Jensen P, Kruse A, Hanberg- Sørensen F, Amdrup E. Controlled clinical trial with sucralfate in the treatment of macroscopic gastritis. Scand J Gastroenterol 1989;24:716-720.   DOI   ScienceOn
12 Kane MP, Briceland LL, Garris RE, Favreau BN. Drug-use review program for concurrent histamine H2-receptor antagonist- sucralfate therapy. Am J Hosp Pharm 1990;47:2007-2010.
13 Mead RA, McGhan WF. Use of histamine2-receptor blocking agents and sucralfate in a health maintenance organization following continued clinical pharmacist intervention. Drug Intell Clin Pharm 1988;22:466-469.   DOI
14 Yates S, Barnett C, Peterson WL. Enteric-coated charcoal as a means of blinding studies comparing bismuth and H2-receptor antagonists. Am J Gastroenterol 1992;87:981-984.
15 Kimura K, Sakai H, Yoshida Y, Kasano T, Hirose M. Effects of concomitant drugs on the blood concentration of a histamine H2 antagonist (the 2nd report)--concomitant or time lag oral administration of ranitidine and sucralfate. Nippon Shokakibyo Gakkai Zasshi 1986;83:603-607.
16 Mullersman G, Gotz VP, Russell WL, Derendorf H. Lack of clinically significant in vitro and in vivo interactions between ranitidine and sucralfate. J Pharm Sci 1986;75:995-998.   DOI
17 Yoshida Y, Kasano T, Kihira K, Hirose M, Kimura K. Effects of concomitant drugs on the blood concentration of a histamine H2 antagonist (the 3rd report)--concomitant or time lag oral administration of cimetidine and sucralfate. Nippon Shokakibyo Gakkai Zasshi 1987;84:1025-1028.
18 Tadashi T, Masayoshi N, Yoshio G, et al. The preliminary study of Efficacy and Dose finding at Ranitidine against acute gastric mucosal disease (transl from Japanese). Clinical Adult Disease 1987;17:147-159.
19 Kim YM, Kim DO, Kim YD, et al. Pharmacokinetics of DWP302, a new combined ranitidine preparations for gastroduodenal diseases. Yakhak Hoeji 1993;37:544-548.